With growing interest by the Pharmaceutical industry to develop new healthcare solutions in the ophthalmic disease area, we have expanded the Ophthalmic and Retinal Disease Category of our Epiomic™ ...
Did you know that June, in terms of daylight hours, is the longest month of the year, despite being only 30 days long? Here’s something else you might not know about June, it’s Migraine Awareness...
Retinal Vein Occlusion (RVO) is a disease in which type and location of occlusion, aetiology and visual complications are all linked to outcomes and treatment requirements. Therefore, knowing the...
Black Swan Analysis will be running an Introduction to UK Pharma Forecasting on behalf of the BHBIA on June the 11th in London. This will be the 4th year in a row that Black Swan Analysis has run...
April marks many things; Easter Sunday, the Thai New Year (this Sunday if you didn’t know) and Testicular Cancer Awareness Month.
Multiple Sclerosis (MS) affects more than 2.3 million people worldwide; March is Multiple Sclerosis Education Awareness Month®, supported by the Multiple Sclerosis Foundation, with the theme, “MS...
Congrats to the Black Swan Analysis team for being nominated for this year’s BOBI award for the 'Agency I would most like to work with'. The competition for the top prize is looking tough this year,...
Access to the Epiomic Hospital Procedure data for the USA and European Region is now available. As part of our core Epiomic database offering to healthcare clients, we have now made available on-line...
https://www.youtube.com/watch?v=tXrtIQ1SUVI
In this article, Christopher Ehinger questions whether rare diseases are a viable option for the pharma industry. He looks at the total number of approvals and orphan drug designations in the US...
